Objective:

To report the early results of CyberKnife® (CK®) stereotactic radiosurgery in advanced stages of ciliochoroidal (CBCh) melanoma in Mexican patients.

Method:

A retrospective review of charts was performed to analyze the outcomes of patients who underwent CK® (Accuray Inc, Sunnyvale, CA, USA).

Results:

Four patients with CBCh melanoma were treated under this protocol. The mean age was 53.2 ± 5.3 years (range: 47-60). Median of follow-up was 9.5 ± 3.1 months (range: 5-12). Mean tumor diameter was 13.49 mm, mean thickness, 11.74 mm, and mean gross tumor volume, 1251.97 mm3. Tumors were dome- (50%) and mushroom-spahed (50%), in medium-to-large sizes. Three patients had T3b tumors, and 1 had a T4d tumor at the early tumor staging according to the American Joint Committee on Cancer (AJCC). A mean dose of 2763 ± 181.3 cGy was prescribed to the 90% isodose line. All patients achieved local tumor control after a single radiosurgical session at the latest follow-up. One patient presented with acute toxicity (extensive serous retinal detachment associated with radiation induced tumor vasculopathy) that was promptly managed. None of the patients required secondary enucleation.

Conclusions:

CK® appears to be an effective therapy for the management of medium-to-large sized CBCh melanoma. A prospective comparative study with longer follow-up is needed to confirm these findings and assess long-term morbidity.

        · resumen en Español     · texto en Español     · Español ( pdf )